Key Takeaways AbbVie posted Q2 EPS of $2.97 on$15.42 billion in revenue, beating estimates and prior company guidance.Strong sales of Rinvoq, Skyrizi, Vraylar and newer drugs offset Humira and Imbruvica declines.ABBV raised full-year 2025 EPS guidance to $11.88-$12.08, up from its prior $11.67-$11.87 range.AbbVie Inc. (ABBV) reported second-quarter 2025 adjusted EPS of $2.97, which beat the Zacks Consensus Estimate of$2.89. The reported figure also exceeded the company’s guidance of $2.84-$2.88 issued ear ...